Department of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410000, Hunan, China.
Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410000, Hunan, China.
Sci Rep. 2022 Jan 18;12(1):871. doi: 10.1038/s41598-022-04946-0.
Metaplastic breast carcinoma (MpBC) is considered a highly aggressive disease, the outcome of chemotherapy on small lesions (T1abcN0M0) MpBC patients remain unclear. We identified 890 female MpBC patients in the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2016. After propensity score matching (PSM), 584 patients were matched. Survival probability was compared among T1a, T1b, and T1c patients and between patients with and without chemotherapy using Kaplan-Meier analysis and Cox proportional hazard analysis. Significance was set at two-sided P < 0.05. We classified 49, 166, and 675 patients as T1a, T1b, and T1c MpBC, respectively. The chemotherapy group included 404 patients (45.4%). Following PSM, survival analysis indicated that the patients who underwent chemotherapy had higher OS (P = 0.0002) and BCSS (P = 0.0276) in the T1c substage, but no significant difference was detected in T1a or T1b patients. In this population-based study, small lesion MpBC showed a favorable prognosis. Chemotherapy improved the prognosis of T1c MpBC patients but not T1a and T1b patients to a beneficial extent. Our findings may offer novel insight into a therapeutic strategy for MpBC.
化生性乳腺癌（MpBC）被认为是一种高度侵袭性疾病，对于小病变（T1abcN0M0）的化疗疗效仍不明确。我们从 2000 年到 2016 年在监测、流行病学和最终结果（SEER）数据库中识别出 890 名女性化生性乳腺癌患者。通过倾向评分匹配（PSM）后，匹配了 584 名患者。使用 Kaplan-Meier 分析和 Cox 比例风险分析比较 T1a、T1b 和 T1c 患者以及化疗患者和未化疗患者的生存概率。双侧 P<0.05 为有统计学意义。我们将 49、166 和 675 名患者分别归类为 T1a、T1b 和 T1c 化生性乳腺癌。化疗组包括 404 名患者（45.4%）。PSM 后，生存分析表明，在 T1c 亚期接受化疗的患者 OS（P=0.0002）和 BCSS（P=0.0276）更高，但在 T1a 或 T1b 患者中未发现显著差异。在这项基于人群的研究中，小病变化生性乳腺癌显示出良好的预后。化疗改善了 T1c 化生性乳腺癌患者的预后，但对 T1a 和 T1b 患者的获益程度没有明显改善。我们的研究结果可能为化生性乳腺癌的治疗策略提供新的见解。
